TWI901650B - 啶及吡啶并〔３，４－ｃ〕嗒衍生物 - Google Patents
啶及吡啶并〔３，４－ｃ〕嗒衍生物Info
- Publication number
- TWI901650B TWI901650B TW110108696A TW110108696A TWI901650B TW I901650 B TWI901650 B TW I901650B TW 110108696 A TW110108696 A TW 110108696A TW 110108696 A TW110108696 A TW 110108696A TW I901650 B TWI901650 B TW I901650B
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- methoxy
- methylpyridin
- tetrahydro
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000113 | 2020-03-26 | ||
| HUP2000113 | 2020-03-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202202495A TW202202495A (zh) | 2022-01-16 |
| TWI901650B true TWI901650B (zh) | 2025-10-21 |
Family
ID=89666363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110108696A TWI901650B (zh) | 2020-03-26 | 2021-03-11 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240067637A1 (enExample) |
| EP (1) | EP4126859A1 (enExample) |
| JP (1) | JP7805946B2 (enExample) |
| KR (1) | KR20220160061A (enExample) |
| CN (1) | CN115348962A (enExample) |
| AR (1) | AR121666A1 (enExample) |
| AU (1) | AU2021244926A1 (enExample) |
| BR (1) | BR112022019128A2 (enExample) |
| CA (1) | CA3171441A1 (enExample) |
| CL (1) | CL2022002568A1 (enExample) |
| CO (1) | CO2022014877A2 (enExample) |
| CU (1) | CU24714B1 (enExample) |
| EC (1) | ECSP22082367A (enExample) |
| GE (2) | GEAP202416066A (enExample) |
| IL (1) | IL296716A (enExample) |
| JO (1) | JOP20220219A1 (enExample) |
| MX (1) | MX2022011933A (enExample) |
| PE (1) | PE20221836A1 (enExample) |
| PH (1) | PH12022552340A1 (enExample) |
| TW (1) | TWI901650B (enExample) |
| WO (1) | WO2021191838A1 (enExample) |
| ZA (1) | ZA202211414B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231691B1 (hu) * | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065215A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | Novel compounds |
| WO2012062687A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Triazole derivatives and their use for neurological disorders |
| WO2014001278A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| US20160102088A1 (en) * | 2014-10-10 | 2016-04-14 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| BRPI0617306A2 (pt) * | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
| BRPI0618383A2 (pt) * | 2005-11-09 | 2011-08-30 | Hoffmann La Roche | derivados de 3-aril-isoxazol-4-carbonil-benzofurano |
| HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| AU2012225805B2 (en) * | 2011-03-04 | 2017-03-02 | Lexicon Pharmaceuticals, Inc. | MST1 kinase inhibitors and methods of their use |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| CA2876778A1 (en) * | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| KR20150033679A (ko) | 2012-06-26 | 2015-04-01 | 사니오나 에이피에스 | 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN102924452B (zh) * | 2012-11-16 | 2015-01-21 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法 |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| CN112409363B (zh) | 2013-12-20 | 2023-11-14 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法 |
| KR20180030545A (ko) * | 2015-06-22 | 2018-03-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 바이사이클릭 헤테로사이클릭 아미드 유도체 |
| JP2018525429A (ja) | 2015-08-28 | 2018-09-06 | アッヴィ・インコーポレイテッド | Ｓ１ｐ調節剤としての縮合複素環化合物 |
| PT3439665T (pt) | 2016-03-18 | 2022-09-27 | Uwm Res Foundation Inc | Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5 |
| UA125524C2 (uk) | 2016-12-08 | 2022-04-13 | Ф. Хоффманн-Ля Рош Аг | Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5 |
| WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| ES2902365T3 (es) | 2017-11-27 | 2022-03-28 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituidos como inhibidores de PDE1 |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| AU2019286312B2 (en) | 2018-06-13 | 2023-08-17 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as GABA A alpha5 PAM |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
-
2021
- 2021-03-11 TW TW110108696A patent/TWI901650B/zh active
- 2021-03-25 GE GEAP202416066A patent/GEAP202416066A/en unknown
- 2021-03-25 MX MX2022011933A patent/MX2022011933A/es unknown
- 2021-03-25 KR KR1020227037372A patent/KR20220160061A/ko active Pending
- 2021-03-25 BR BR112022019128A patent/BR112022019128A2/pt unknown
- 2021-03-25 PE PE2022002114A patent/PE20221836A1/es unknown
- 2021-03-25 CU CU2022000058A patent/CU24714B1/es unknown
- 2021-03-25 GE GEAP202116066A patent/GEP20257761B/en unknown
- 2021-03-25 CA CA3171441A patent/CA3171441A1/en active Pending
- 2021-03-25 WO PCT/IB2021/052486 patent/WO2021191838A1/en not_active Ceased
- 2021-03-25 JP JP2022557102A patent/JP7805946B2/ja active Active
- 2021-03-25 IL IL296716A patent/IL296716A/en unknown
- 2021-03-25 EP EP21715334.5A patent/EP4126859A1/en active Pending
- 2021-03-25 AU AU2021244926A patent/AU2021244926A1/en active Pending
- 2021-03-25 CN CN202180023958.0A patent/CN115348962A/zh active Pending
- 2021-03-25 PH PH1/2022/552340A patent/PH12022552340A1/en unknown
- 2021-03-25 US US17/907,174 patent/US20240067637A1/en active Pending
- 2021-03-26 AR ARP210100754A patent/AR121666A1/es unknown
-
2022
- 2022-09-13 JO JOP/2022/0219A patent/JOP20220219A1/ar unknown
- 2022-09-22 CL CL2022002568A patent/CL2022002568A1/es unknown
- 2022-10-18 ZA ZA2022/11414A patent/ZA202211414B/en unknown
- 2022-10-19 CO CONC2022/0014877A patent/CO2022014877A2/es unknown
- 2022-10-22 EC ECSENADI202282367A patent/ECSP22082367A/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065215A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | Novel compounds |
| WO2012062687A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Triazole derivatives and their use for neurological disorders |
| WO2014001278A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| US20160102088A1 (en) * | 2014-10-10 | 2016-04-14 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022019128A2 (pt) | 2022-11-08 |
| TW202202495A (zh) | 2022-01-16 |
| PH12022552340A1 (en) | 2023-11-29 |
| PE20221836A1 (es) | 2022-11-29 |
| AR121666A1 (es) | 2022-06-29 |
| US20240067637A1 (en) | 2024-02-29 |
| JOP20220219A1 (ar) | 2022-09-13 |
| CA3171441A1 (en) | 2021-09-30 |
| GEP20257761B (en) | 2025-04-10 |
| ZA202211414B (en) | 2023-06-28 |
| JP7805946B2 (ja) | 2026-01-26 |
| GEAP202416066A (en) | 2024-12-10 |
| KR20220160061A (ko) | 2022-12-05 |
| AU2021244926A1 (en) | 2022-11-03 |
| CU20220058A7 (es) | 2023-05-11 |
| EP4126859A1 (en) | 2023-02-08 |
| CO2022014877A2 (es) | 2022-10-31 |
| IL296716A (en) | 2022-11-01 |
| CN115348962A (zh) | 2022-11-15 |
| JP2023520647A (ja) | 2023-05-18 |
| ECSP22082367A (es) | 2022-11-30 |
| CU24714B1 (es) | 2024-07-10 |
| CL2022002568A1 (es) | 2023-03-24 |
| WO2021191838A1 (en) | 2021-09-30 |
| MX2022011933A (es) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2531501T3 (en) | APOPTOSESIGNALREGULERENDE KINASE 1 inhibitors | |
| US8785481B2 (en) | Ether benzotriazole derivatives | |
| JP2002507996A (ja) | 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類 | |
| TW200916469A (en) | Multi-cyclic compounds | |
| TW201002716A (en) | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | |
| EP3856342B1 (en) | Bicyclic derivatives as gabaa a5 receptor modulators | |
| EP4126858B1 (en) | Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators | |
| JP7805946B2 (ja) | ＧＡＢＡ Ａアルファ５受容体調節剤としてのナフチリジンおよびピリド［３，４－ｃ］ピリダジン誘導体 | |
| EP3137469A1 (en) | Heterocyclic compounds and their use as dopamine d1 ligands | |
| TW202330518A (zh) | 作為ＧＡＢＡＡ α５受體調節劑之雙環胺衍生物 | |
| US6277993B1 (en) | Intermediates for 5-substituted-3-oxadiazolyl-1,6-Naphthyridin-2(1H)-one derivatives | |
| EA049237B1 (ru) | ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA | |
| EA052124B1 (ru) | БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA | |
| EA045543B1 (ru) | БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA |